Literature DB >> 10639657

In situ microdialysis in tendon tissue: high levels of glutamate, but not prostaglandin E2 in chronic Achilles tendon pain.

H Alfredson1, K Thorsen, R Lorentzon.   

Abstract

This investigation was to our knowledge the first to use the microdialysis technique to study concentrations of substances in a human tendon. In four patients (mean age 40.7 years) with a painful nodule in the Achilles tendon (chronic Achilles tendinosis) and in five controls (mean age 37.2 years) with normal Achilles tendons (confirmed by ultrasonography) the local concentrations of glutamate and prostaglandin E2 were measured under resting conditions. A standard microdialysis catheter was inserted into the Achilles tendon under local anesthesia. Sampling was performed every 15 min over a 4-h period. The results showed significantly higher concentrations of glutamate in tendons with tendinosis than in normal tendons (196 +/- 59 vs. 48 +/- 27 mumol/l, P < 0.05), and there were no significant changes in glutamate concentration over the period of investigation. There were no significant differences in the mean concentrations of prostaglandin E2 (83 +/- 22 vs. 54 +/- 24 pg/ml) between tendons with tendinosis and normal tendons. In conclusion, in situ microdialysis appears a useful method to study certain metabolic events in tendon tissue. The higher concentrations of the excitatory neurotransmitter glutamate in Achilles tendons with a painful nodule may possibly be involved in the pain mechanism in this chronic condition. Furthermore, there were no signs of inflammation in the tendons with painful nodules, as indicated by the normal prostaglandin E2 levels.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10639657     DOI: 10.1007/s001670050184

Source DB:  PubMed          Journal:  Knee Surg Sports Traumatol Arthrosc        ISSN: 0942-2056            Impact factor:   4.342


  60 in total

1.  A randomised clinical trial of the efficacy of drop squats or leg extension/leg curl exercises to treat clinically diagnosed jumper's knee in athletes: pilot study.

Authors:  L J Cannell; J E Taunton; D B Clement; C Smith; K M Khan
Journal:  Br J Sports Med       Date:  2001-02       Impact factor: 13.800

2.  Where is the pain coming from in tendinopathy? It may be biochemical, not only structural, in origin.

Authors:  K M Khan; J L Cook; N Maffulli; P Kannus
Journal:  Br J Sports Med       Date:  2000-04       Impact factor: 13.800

3.  VO2 slow component and performance in endurance sports.

Authors:  V L Billat
Journal:  Br J Sports Med       Date:  2000-04       Impact factor: 13.800

4.  Fortnightly review: Corticosteroid injections in tendon lesions.

Authors:  C A Speed
Journal:  BMJ       Date:  2001-08-18

Review 5.  Achilles tendinopathy: some aspects of basic science and clinical management.

Authors:  D Kader; A Saxena; T Movin; N Maffulli
Journal:  Br J Sports Med       Date:  2002-08       Impact factor: 13.800

Review 6.  What do we mean by the term "inflammation"? A contemporary basic science update for sports medicine.

Authors:  A Scott; K M Khan; C R Roberts; J L Cook; V Duronio
Journal:  Br J Sports Med       Date:  2004-06       Impact factor: 13.800

Review 7.  The pain of tendinopathy: physiological or pathophysiological?

Authors:  Ebonie Rio; Lorimer Moseley; Craig Purdam; Tom Samiric; Dawson Kidgell; Alan J Pearce; Shapour Jaberzadeh; Jill Cook
Journal:  Sports Med       Date:  2014-01       Impact factor: 11.136

8.  Chronic Achilles tendinosis: recommendations for treatment and prevention.

Authors:  H Alfredson; R Lorentzon
Journal:  Sports Med       Date:  2000-02       Impact factor: 11.136

9.  Tendon and ligament imaging.

Authors:  R J Hodgson; P J O'Connor; A J Grainger
Journal:  Br J Radiol       Date:  2012-05-02       Impact factor: 3.039

10.  The long-term clinical and MRI results following eccentric calf muscle training in chronic Achilles tendinosis.

Authors:  Anna Gärdin; Tomas Movin; Leif Svensson; Adel Shalabi
Journal:  Skeletal Radiol       Date:  2009-09-23       Impact factor: 2.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.